Adrian Hugenmatter, PhD

Critic
DISC Type : C

Head of Protein Therapeutics at Stanford University

Palo Alto, California, United States

Overview

Dr. Adrian Hugenmatter directs Protein Engineering at Stanfords Sarafan ChEM-H and leads Protein Therapeutics at the Innovative Medicines Accelerator. With a PhD from ETH Zürich and industry experience at Roche, he is a self-described "drug hunter" focused on creating novel protein-based medicines that combine high therapeutic efficacy with maximum safety.

He is an entrepreneur in the biotech space, having co-founded Spire Biotechnology. His work is driven by a passion for realizing new, innovative solutions in drug research through clever protein engineering and interdisciplinary collaboration.

Unique fact: He holds a certification in "Business Creation BIOTECH, " underscoring his interest in the commercialization of scientific discoveries.

Personality Overview

Precise

Critic

Objective Thinker

They don’t appreciate bells and whistles unless backed by data.  They are quite likely to negotiate on pricing or other key terms. They like to do things independently and don’t look for support from others.

Topics They Care About

Protein Engineering
As Director of Protein Engineering, his daily work involves using "clever and innovative protein engineering" to design ideal drugs for patients.
Innovative Drug Discovery
He is constantly searching for new mechanisms of action and technologies to treat various diseases, reflecting a core passion for novel therapeutic solutions.
Therapeutic Efficacy
A central question driving his work is how to combine the highest therapeutic efficacy and maximum safety in a single molecule for patient benefit.

Media Appearances

Adrian has no verified media appearances

Work History

9-2021
Head of Protein Therapeutics at Stanford University
9-2021 - 10-2025
Director of Protein Engineering at Stanford University
5-2021 - 11-2023
Co-Founder at Spire Biotechnology
8-2012 - 8-2021
Senior Research Scientist at Roche
2-2010 - 8-2012
Research Scientist at Roche

Education

2000 - 2006
PhD from ETH Zürich
1995 - 2000
Diploma from ETH Zürich

More Information

Social Presence :

Prographics :

Exp : 26 Location : Palo Alto, California, United States Job Level : Mid-senior Designation : Head of Protein Therapeutics at Stanford University
URL has been copied!

Insights For Selling To Adrian

During A Call Or A Meeting

DO's

  • Tell them what ROI they can expect
  • If you can, show them industry reports or analyst comments instead of sharing anecdotal stories
  • Don’t forget to mention how you compare to competition on both features and pricing

DONT's

  • Don’t rush them till they have clearly gotten all the necessary information
  • Don’t try too hard to build a relationship with them
  • Do not use very emotional or colorful language

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Adrian is

  • Proven ROI, pricing and objective proof points are the factors that sway their decision.
  • Will you ever get a clear answer from Adrian

  • They are comfortable saying no if they are convinced that it is the correct decision.

Insights For Deal Planning

    How fast (or slow) will Adrian move?

  • They are neither the fastest nor the slowest decision makers, they are somewhere in the middle.
  • Can Adrian take some risk or not?

  • They can bear some risk if their analysis backs the decision.

You And Adrian

Personality Compatibility


Other Stanford University Employees

Explore more public profiles from related professionals at the same organization.

More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.